508 related articles for article (PubMed ID: 34161115)
1. Neutrophil-to-lymphocyte ratio, past, present and future perspectives.
Zahorec R
Bratisl Lek Listy; 2021; 122(7):474-488. PubMed ID: 34161115
[TBL] [Abstract][Full Text] [Related]
2. Zahorec index or Neutrophil-to-lymphocyte ratio, valid biomarker of inflammation and immune response to infection, cancer and surgery.
Firment J; Hulin I
Bratisl Lek Listy; 2024; 125(2):75-83. PubMed ID: 38219059
[TBL] [Abstract][Full Text] [Related]
3. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill.
Zahorec R
Bratisl Lek Listy; 2001; 102(1):5-14. PubMed ID: 11723675
[TBL] [Abstract][Full Text] [Related]
4. Elevated neutrophil-lymphocyte ratio predicts mortality following elective endovascular aneurysm repair.
King AH; Schmaier AH; Harth KC; Kumins NH; Wong VL; Zidar DA; Kashyap VS; Cho JS
J Vasc Surg; 2020 Jul; 72(1):129-137. PubMed ID: 32037083
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
7. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
9. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.
Lian L; Xia YY; Zhou C; Shen XM; Li XL; Han SG; Zheng Y; Mao ZQ; Gong FR; Wu MY; Chen K; Tao M; Li W
Cancer Biomark; 2015; 15(6):899-907. PubMed ID: 26444485
[TBL] [Abstract][Full Text] [Related]
10. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.
Cheng H; Luo G; Lu Y; Jin K; Guo M; Xu J; Long J; Liu L; Yu X; Liu C
Pancreatology; 2016; 16(6):1080-1084. PubMed ID: 27665172
[TBL] [Abstract][Full Text] [Related]
11. [Dynamic monitoring of the neutrophil/lymphocyte ratio could predict the prognosis of patients with bloodstream infection].
Yang M; Li L; Su N; Lin J; Wang J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Jun; 27(6):471-6. PubMed ID: 26049186
[TBL] [Abstract][Full Text] [Related]
12. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-To-Lymphocyte Ratio and Systemic Immune-Inflammation Index-Biomarkers in Interstitial Lung Disease.
Ruta VM; Man AM; Alexescu TG; Motoc NS; Tarmure S; Ungur RA; Todea DA; Coste SC; Valean D; Pop MC
Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32751302
[No Abstract] [Full Text] [Related]
14. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer.
Mizuguchi S; Izumi N; Tsukioka T; Komatsu H; Nishiyama N
J Cardiothorac Surg; 2018 Jun; 13(1):78. PubMed ID: 29945635
[TBL] [Abstract][Full Text] [Related]
16. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma.
Fu X; Li T; Dai Y; Li J
BMC Cancer; 2019 Jul; 19(1):721. PubMed ID: 31331297
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of neutrophil to lymphocyte and monocyte to lymphocyte ratios as new inflammatory markers in acute coronary syndrome.
Shumilah AM; Othman AM; Al-Madhagi AK
BMC Cardiovasc Disord; 2021 Sep; 21(1):422. PubMed ID: 34493205
[TBL] [Abstract][Full Text] [Related]
19. Limited value of neutrophil-to-lymphocyte ratio and serum creatinine as point-of-care biomarkers of disease severity and infection mortality in patients hospitalized with COVID-19.
Tufa A; Gebremariam TH; Manyazewal T; Asrat Y; Getinet T; Hundie TG; Webb DL; Hellström PM; Genet S
PLoS One; 2022; 17(10):e0275391. PubMed ID: 36201435
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete Resection.
Takahashi Y; Kawamura M; Hato T; Harada M; Matsutani N; Horio H
World J Surg; 2016 Feb; 40(2):365-72. PubMed ID: 26493696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
